Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 2002;33:1934-1942
doi: 10.1161/01.STR.0000028456.18614.93
Free Article
This Article
Free upon publication Free Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Coull, B.M.
Right arrow Articles by Saver, J.L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Coull, B.M.
Right arrow Articles by Saver, J.L.
Related Collections
Right arrow Cardiac development

(Stroke. 2002;33:1934.)
© 2002 American Heart Association, Inc.


ASA/AAN Scientific Statement

Anticoagulants and Antiplatelet Agents in Acute Ischemic Stroke

Report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a Division of the American Heart Association)

B.M. Coull, MD; L.S. Williams, MD; L.B. Goldstein, MD; J.F. Meschia, MD; D. Heitzman, MD; S. Chaturvedi, MD; K.C. Johnston, MD; S. Starkman, MD; L.B. Morgenstern, MD; J.L. Wilterdink, MD; S.R. Levine, MD J.L. Saver, MD

From the Department of Neurology (B.M.C.), Arizona Health Science Center, Tucson, Ariz; Department of Neurology (L.S.W.), Indiana University School of Medicine, Research Scientist, Regenstrief Institute for Health Care, Indianapolis, Ind; Department of Neurology (L.B.G.), Duke Center for Cerebrovascular Disease, Duke Center for Clinical Health Policy Research, and Durham VA Medical Center, Durham, NC; Department of Neurology (J.F.M.), Mayo Clinic/Jacksonville, Fla; Texas Neurology, PC (D.H.), Dallas, Tex; Department of Neurology (S.C.), Wayne State University, Detroit, Mich; Departments of Neurology and Health (K.C.J.), Evaluation Sciences, University of Virginia, Charlottesville; Departments of Emergency Medicine and Neurology (S.S.), UCLA, and Department of Neurology (J.L.S.), UCLA School of Medicine, Los Angeles, Calif; Departments of Neurology & Epidemiology (L.B.M.), University of Texas, Houston; Department of Clinical Neurosciences (J.L.W.), Brown Medical School, Providence, RI; and Department of Neurology (S.R.L.), Mount Sinai School of Medicine, New York, NY.

Correspondence and reprint requests to American Academy of Neurology, 1080 Montreal Ave., St. Paul, MN 55116.


An extract of the first 250 words of the full text is provided, because this article has no abstract.
 

Stroke remains a common and costly problem worldwide, but substantial advances have been made in recent decades in understanding stroke mechanisms, risk factors, and therapies. Because thrombosis plays an important role in the pathogenesis of ischemic stroke, drugs that interfere with hemostasis and clot formation such as anticoagulants and platelet antiaggregants commonly are used in the management of cerebrovascular disease. Considerable evidence supports the use of certain antithrombotic drugs in stroke prevention. However, because of limited supportive data, the use of these agents in patients with acute ischemic stroke remains controversial.

In this report, we examine the published evidence relevant to the effects of anticoagulants and antiplatelet agents on acute ischemic stroke mortality, morbidity, and recurrence rates as well as associated ancillary benefits and risks of those treatments on the rates of deep vein thrombosis, pulmonary embolus, and cardiovascular complications. As part of these analyses, we also sought to determine whether there was evidence supporting differential efficacy of these drugs according to ischemic stroke subtypes.

Methods

To prepare this report, experienced neurologists with a special interest in stroke diagnosis and management were appointed by the Quality Standards Subcommittee (QSS) and the Therapeutics and Technology Assessment (TTA) Subcommittee of the American Academy of Neurology, and the Stroke Council and Science Advisory and Coordinating Committee (SACC) of the American Heart Association (AHA). The QSS, TTA, Stroke Council and SACC are each charged with the responsibility of preparing evidence-based reports pertaining to medical practice issues including stroke.

To facilitate the process of joint guideline . . . [Full Text of this Article]




This article has been cited by other articles:


Home page
Mayo Clin Proc.Home page
K. M. Barrett and W. D. Freeman
71-Year-Old Woman With Loss of Right-Sided Vision and Cognitive Deficits
Mayo Clin. Proc., June 1, 2008; 83(6): 708 - 711.
[Full Text] [PDF]


Home page
ChestHome page
G. W. Albers, P. Amarenco, J. D. Easton, R. L. Sacco, and P. Teal
Antithrombotic and Thrombolytic Therapy for Ischemic Stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest, June 1, 2008; 133(6_suppl): 630S - 669S.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
S. T. Engelter, T. Brandt, S. Debette, V. Caso, C. Lichy, A. Pezzini, S. Abboud, A. Bersano, R. Dittrich, C. Grond-Ginsbach, et al.
Antiplatelets Versus Anticoagulation in Cervical Artery Dissection
Stroke, September 1, 2007; 38(9): 2605 - 2611.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
H. P. Adams Jr, G. del Zoppo, M. J. Alberts, D. L. Bhatt, L. Brass, A. Furlan, R. L. Grubb, R. T. Higashida, E. C. Jauch, C. Kidwell, et al.
Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists.
Circulation, May 22, 2007; 115(20): e478 - e534.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
H. P. Adams Jr, G. del Zoppo, M. J. Alberts, D. L. Bhatt, L. Brass, A. Furlan, R. L. Grubb, R. T. Higashida, E. C. Jauch, C. Kidwell, et al.
Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/ American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists
Stroke, May 1, 2007; 38(5): 1655 - 1711.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
P. Sandercock
Immediate Anticoagulation for Acute Stroke in Atrial Fibrillation: No
Stroke, December 1, 2006; 37(12): 3054 - 3055.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. C. Smith Jr, J. Allen, S. N. Blair, R. O. Bonow, L. M. Brass, G. C. Fonarow, S. M. Grundy, L. Hiratzka, D. Jones, H. M. Krumholz, et al.
AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update: Endorsed by the National Heart, Lung, and Blood Institute
J. Am. Coll. Cardiol., May 16, 2006; 47(10): 2130 - 2139.
[Full Text] [PDF]


Home page
CirculationHome page
S. C. Smith Jr, J. Allen, S. N. Blair, R. O. Bonow, L. M. Brass, G. C. Fonarow, S. M. Grundy, L. Hiratzka, D. Jones, H. M. Krumholz, et al.
AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update: Endorsed by the National Heart, Lung, and Blood Institute
Circulation, May 16, 2006; 113(19): 2363 - 2372.
[Full Text] [PDF]


Home page
StrokeHome page
H. F. McGruder, J. B. Croft, and Z.-J. Zheng
Characteristics of an "Ill-Defined" Diagnosis for Stroke: Opportunities for Improvement
Stroke, March 1, 2006; 37(3): 781 - 789.
[Abstract] [Full Text] [PDF]


Home page
Am J Health Syst PharmHome page
S. Lam and C. M. Ruby
Impact of an interdisciplinary team on drug therapy outcomes in a geriatric clinic
Am. J. Health Syst. Pharm., March 15, 2005; 62(6): 626 - 629.
[Full Text] [PDF]


Home page
ChestHome page
G. W. Albers, P. Amarenco, J. D. Easton, R. L. Sacco, and P. Teal
Antithrombotic and Thrombolytic Therapy for Ischemic Stroke: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Chest, September 1, 2004; 126(3_suppl): 483S - 512S.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
H. P. Adams Jr, R. J. Adams, T. Brott, G. J. del Zoppo, A. Furlan, L. B. Goldstein, R. L. Grubb, R. Higashida, C. Kidwell, T. G. Kwiatkowski, et al.
Guidelines for the Early Management of Patients With Ischemic Stroke: A Scientific Statement From the Stroke Council of the American Stroke Association
Stroke, April 1, 2003; 34(4): 1056 - 1083.
[Full Text] [PDF]


Home page
StrokeHome page
X. Wang, L. Xu, H. Wang, R. Grzanna, Y. Zhan, R. M. Knabb, J. M. Luettgen, T. A. Bozarth, R. A. Galemmo, P. C. Wong, et al.
Inhibition of Factor Xa Reduces Ischemic Brain Damage After Thromboembolic Stroke in Rats
Stroke, February 1, 2003; 34(2): 468 - 474.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
P. Sandercock
Full Heparin Anticoagulation Should Not Be Used in Acute Ischemic Stroke
Stroke, January 1, 2003; 34(1): 231 - 232.
[Full Text] [PDF]